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ABSTRACT
Expression of amyloid precursor protein (APP) is
critical to the etiology of Alzheimer’s disease (AD).
Consequently, regulating APP expression is one
approach to block disease progression. To this
end, APP can be targeted at the levels of transcrip-
tion, translation, and protein stability. Little is cur-
rently known about the translation of APP mRNA.
Here, we report that endogenous APP mRNA is
translated in neural cell lines via an internal ribo-
some entry site (IRES) located in the 5’-untranslated
leader. The functional unit of the APP IRES is
located within the 5’50 nucleotides of the
5’-leader. In addition, we found that the APP IRES
is positively regulated by two conditions correlated
with AD, increased intracellular iron concentration
and ischemia. Interestingly, the enhancement of
APP IRES activity is dependent upon de novo trans-
cription. Taken together, our data suggest that
internal initiation of translation of the APP mRNA is
an important mode for synthesis of APP, a mecha-
nism which is regulated by conditions that also
contribute to AD.
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disorder
characterized by the presence of intracellular neuroﬁbril-
lary tangles as well as extracellular plaques composed of
aggregates of b-amyloid peptide (Ab) in the brain. Ab is
central to the pathophysiology of AD and may initiate the
disorder (1). The peptide is derived from the sequential
cleavage of amyloid precursor protein (APP) by two pro-
teases, b- and g-secretase. A b-secretase (Bace1) (2) and
the catalytic subunits of the g-secretase, presenilin 1 and 2
(PS1 and PS2) (3,4) are now accepted as genes that play
an essential role in the onset and progression of the
disease (5).
If expression of the Ab peptide is a major contributor to
the etiology of AD, then a logical target for amelioration of
the disease is to regulate the cleavage of its precursor pro-
tein, APP, into the Ab peptide products. An alternative
approach would be to regulate availability of APP itself,
which should also decrease levels of the Ab peptide.
Multiple avenues may be amenable to alter APP expres-
sion. For example, transcription of the APP gene has been
well studied with identiﬁcation of cell type-speciﬁc pro-
moter regions and diﬀerent promoter alleles that may con-
tribute to AD (6–9). Once APP has been translated,
reducing APP protein stability could decrease the likeli-
hood of its cleavage by secretases. However, nascent APP
already exhibits a short half-life (ranging from 20min to
90min) (10–12) and once it is cleaved, the Ab peptide is
very stable and insoluble, likely making it diﬃcult to
further aﬀect protein half-life or increase peptide solubility.
Translation initiation is an additional process to regu-
late protein expression (13). The main form of initiation in
eukaryotes is cap-dependent translation, which relies upon
the rate-limiting protein eukaryotic initiation factor (eIF)
4E to bind the 7-methyl-guanosine (m7G) cap structure at
the 50-end of the mRNA. eIF-4E subsequently recruits the
scaﬀolding protein eIF-4G, to which the remainder of the
translational machinery (including the 40S ribosomal sub-
unit and methionine-loaded tRNA) is attached, forming
the 43S pre-initiation complex [for review, see Ref. (14)].
The 43S complex is proposed to then migrate or scan
along the mRNA 50-leader until it encounters the ﬁrst
initiator codon (AUG). Upon recognition of the initiator
codon by the 43S complex, GTP hydrolysis occurs, the
60S ribosomal subunit joins the 40S subunit to form the
80S ribosome, translation initiation factors are liberated
and peptide synthesis ensues (15,16).
Cap-dependent translation is diminished during mitosis
(17) as well as in reaction to cellular stressors such as
decreased oxygen supply resulting from ischemia (18).
Cap-dependent translation is also inhibited in response
to particular viral infections, such as poliovirus (19). In
response to these stressors, a subset of eukaryotic mRNAs
continue to be translated via initiation at an internal
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50-leader (20–23). IRESes directly recruit translational
machinery, independently of the 50-m7G cap structure
and enable a select pool of mRNAs to be translated in
response to conditions when global or cap-dependent
translation is inhibited (24). Moreover, recent studies
have found that cells containing mutations in the dyskerin
gene exhibit a decrease in the expression of a selective
group of proteins via a disruption in the internal initiation
of translation of their mRNAs (25). This result indicates
that IRES-dependent translation may be a primary trans-
lational mechanism for a subset of mRNAs.
Recent evidence indicates that the APP mRNA may be
translated through an IRES. Qin and Sarnow (17) found
that APP mRNA is one of several mRNAs which remain
associated with polyribosomes during mitosis, when cap-
dependent translation is greatly reduced. In addition,
translation of a second cistron from a dicistronic DNA
construct increased when the APP 50-leader was placed
into its intercistronic region (17). However, many ques-
tions remain and some reports have challenged the use
of dicistronic DNA constructs to assay IRES activity.
The presence of a cryptic promoter or cryptic splice accep-
tor site in the DNA sequence of a 50-leader may generate
RNA species which only contain the open reading frame
(ORF) for the second cistron (26). The resulting monocis-
tronic RNA would lead to an artifactual increase in the
expression of the second cistron (27). Perhaps more
importantly, it is not known whether IRES-dependent
translation is a physiologically signiﬁcant mechanism for
APP expression in vivo and whether cap- and/or IRES-
dependent translation is utilized under conditions in
which APP synthesis is upregulated, thus promoting pro-
gression of AD.
Several studies suggest a role for elevated intracellular
iron in the etiology of AD (28). During normative aging,
there is an increase in both iron and the iron-sequestering
protein, ferritin, in the central nervous system. However, in
AD patients, there is a further enrichment of iron in the
brain without the concomitant increase in ferritin (29,30).
This increased level of labile iron is available to participate
in the formation of reactive oxygen species and contributes
to multiple cellular reactions which promote AD; the
synthesis of APP, the rate of Ab oligomerization, aggrega-
tion and precipitation are all enhanced through its interac-
tion with iron (31,32). Once in an extracellular plaque, iron
can enhance Ab toxicity through the generation of hydro-
xyl radicals and the resulting oxidative stress (33).
Perturbations in the cerebral vasculature which induce
ischemic conditions in the brain are also proposed to be a
causal factor for AD [for reviews, see Refs (34,35)].
Indeed, at autopsy most AD patient brains exhibit pathol-
ogy of prior cerebrovascular damage (36), including
vascular irregularities as well as a decrease in capillary
density (37). Recent data also suggest that ischemia and
reperfusion lead to the sequestration of canonical cap-
dependent translation factors into mRNA storage bodies
in rat hippocampus, leading to a global translational
arrest (38). Despite this ﬁnding, ischemia has also been
shown to lead to an increase in APP expression (39) and
cleavage (40).
Interestingly, both elevated intracellular iron levels
and ischemia individually appear to promote AD at the
level of translation. Despite the global inhibition of cap-
dependent protein synthesis imparted by these cellular
stressors (41,42), APP expression is enhanced (32,43).
These results support the hypothesis that APP synthesis
takes place via an alternate translation initiation mecha-
nism allowing for it to be synthesized even under these
conditions. Indeed, in the present report we validate the
initial report that the APP 50-leader contains an IRES and
show that IRES-dependent translation is a mechanism by
which endogenous APP mRNA is translated. Moreover,
increased intracellular iron levels and chemical ischemia
both augment APP IRES activity and endogenous APP
synthesis in neural cell lines. These results indicate that
the APP IRES may be a target for regulating APP expres-
sion in vivo.
MATERIALS AND METHODS
Cloning, reporter constructs and RNA transcription
PCR primers were designed to amplify the 50-leader of
the human APP and b-globin (GenBank accession num-
bers: APP, NM_000484; b-globin, V00497) mRNAs from
human adult brain cDNA. A 4-nt deletion ( 64 AGAG
 61) in the APP 50-leader (APP) was generated by Gene
Tailor Site Directed Mutagenesis System (Invitrogen,
Carlsbad, CA, USA). The 50-leaders were inserted into an
EcoRI and NcoI restriction site between the Renilla lucifer-
ase and the Photinus luciferase cistrons of a dicistronic con-
struct (44) and subcloned into the PBluescript II SK (+)
vector (Stratagene, La Jolla, CA, USA). Monocistronic
luciferase constructs (45) containing the 50-leader upstream
of the Photinus luciferase ORF were also subcloned into
PBluescript II SK (+). Dicistronic and monocistronic
RNA were in vitro transcribed from linearized plasmids
and poly A tailed, all according to the manufacturer’s
protocol, using mMessage mMachine T7 and mMessage
mMachine T7 Ultra (Ambion, Austin, TX, USA), respec-
tively. For studies comparing translation from untailed
m7G-capped mRNAs to that from ApppG-capped
mRNAs, Megascript T7 (Ambion) was used to in vitro
transcribe the transcripts with ApppG cap analog (New
England Biolabs, Ipswich, MA) used in place of m7G cap
analog in the reaction. All RNAs were heat-denatured, run
on nondenaturing 3-(N-morpholino) propanesul fonic acid
(MOPS) agarose gels (Lonza Rockland Inc., Rockland,
ME, USA), and visualized with SYBR gold to check their
size and integrity prior to transfection in cells.
Cell culture
C6 and SH-SY5Y cells were obtained from American
Type Culture Collection (ATCC) (Manassas, VA) and
grown in complete culture medium: Dubelco’s Modiﬁed
Eagle Medium (DMEM; Sigma Aldrich, St Louis, MO,
USA) supplemented with 10% fetal bovine serum
(FBS; Sigma Aldrich) and 1% penicillin (10000U/ml)/
streptomycin (10000mg/ml)/glutamine (29.2mg/ml)
(Cellgro, Herdon, VA, USA).
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C6 cells were plated at a density of 1.0 10
5, 17h prior to
transfection. Immediately prior to transfection, complete
growth media described above was refreshed. Cells were
transfected using FuGene6 transfection reagent (Roche,
Indianapolis, IA, USA) with 1mg of dicistronic DNA con-
struct. Cells were lysed with 400ml1   Passive Lysis Buﬀer
(Promega, Madison, WI, USA) for 15min at room tem-
perature with rocking. Fifty microliters of the lysate was
assayed for luciferase activity using the dual reporter assay
system (Promega) in a Luminoskan Ascent luminometer
(Thermo Labsystems, Franklin, MA).
Monocistronic and dicistronic RNA transfection
C6 cells were plated at a density of 1 10
6 in 35-mm well
plates for 17h. Cells were rinsed with PBS and complete
culture media (described above) was replaced with serum-
free media (DMEM containing Glutamine, Sigma
Aldrich). Cells were then transfected with 4mg of dicistro-
nic m7G-capped and tailed reporter RNAs with 16mlo f
TransMessenger transfection reagent (Qiagen, Valencia,
CA, USA). After 3h, the cells were rinsed with PBS and
complete culture media was added for an additional 4h.
Cells were rinsed with PBS and lysed with 400mlo f1  
Passive Lysis Buﬀer (Promega) for 15min at room tem-
perature with rocking. Fifty microliters of lysate was
assayed for luciferase activity using the dual reporter
assay system (Promega) in a Luminoskan Ascent lumin-
ometer (Thermo Labsystems). For monocistronic RNA
transfections, the same transfection protocol was fol-
lowed, except that C6 cells were co-transfected with 2mg
of either m7G-capped or ApppG-capped monocistronic
Photinus luciferase RNA along with 2mg of an m7G-
capped Renilla luciferase RNA to control for transfection
eﬃciency.
Cellular treatments
To study the eﬀect of iron on IRES activity, cells were
exposed to 50mM of ferric ammonium citrate (FAC;
Sigma Aldrich) and/or 2.5mg/ml of Actinomycin D
(Calbiochem, San Diego, CA, USA). Cells were treated
for a total of 24h: 17h before the RNA transfection, 3h
during the transient RNA transfection and 4h after the
RNA transfection. To study the eﬀect of ischemia on
IRES activity, C6 cells were exposed to 10mM sodium
azide (Acros organics, Morris Plains, NJ, USA) and
10mM dideoxyglucose (Calbiochem) for 10min. The
cells were then rinsed with PBS and transfected with
RNA. For ex vivo studies using rapamycin (Sigma
Aldrich), C6 cells were treated with 40 nM rapamycin
(Sigma Aldrich) for 16h. In studies using cycloheximide
(Sigma Aldrich), C6 cells were treated with 300mg/ml
cycloheximide in complete cell culture media for 0min,
30min, 60min, 90min, 120min or 180min prior to har-
vest using 200mlo f1   cell culture lysis buﬀer (Promega)
containing phosphatase inhibitors (Pierce, Rockford,
IL, USA) and protease inhibitors (Roche) as per manu-
facturer’s speciﬁcations. Lysates were either immediately
used for western blotting or immediately stored at  808C.
GraphPad Prism software was used to calculate half-life
using the nonlinear one-phase decay equation.
Cellular siRNA treatments
Nonsense siRNA of 10mM (Dharmacon, Thermo Scien-
tiﬁc, Lafayette, CO, USA, D-001206-13-20) or rat eIF-4E
siRNA (Dharmacon, L-088826-01-0010) were incubated
in 35-mm plate wells with 12ml of Interferin transfection
reagent (PolyPlus-transfection, NY, USA, 40950) at 378C
for 10min. During this time, cultured C6 cells were plated
at 1.0 10
6 in wells already containing siRNA complexes
and serum-free growth media. Complete growth media
was then added to a ﬁnal volume of 2.2ml. Cells were har-
vested after 72h with 200mlo f1   cell culture lysis buﬀer
(Promega) containing phosphatase inhibitors (Pierce) and
protease inhibitors (Roche) as per manufacturer’s speciﬁ-
cations. Lysates were either immediately stored at  808C
or used for western blotting.
Invitro translation
Capped and tailed monocistronic RNAs were in vitro
translated in micrococcal nuclease-treated rabbit reticulo-
cyte lysate (SpeedRead Lysates, Novagen, Madison, WI,
USA). The 0.5mg of RNA, 100mM of KCl, 0.25mM of
Mg acetate, 312.5mM methionine and increasing concen-
trations of m7G cap analog (New England Biolabs) were
added to the reaction and incubated for 1h at 308C.
Luciferase activity was then measured as detailed above.
To verify stability of the transcripts following reactions,
RNA was isolated from each rabbit reticulocyte lysate
(RRL) reaction using MegaClear (Ambion). RNA (1mg
of each) was then analyzed by northern blot analysis and
probed with DIG-labeled RNA probe against Photinus
luciferase.
Westernblot analysis
Cells were harvested with 1  cell culture lysis buﬀer
(Promega) with protease and phosphatase inhibitors
(Roche). The cell lysate was analyzed via western blotting
by separating the proteins on a 10% SDS–polyacrylamide
gel with subsequent transfer onto nitrocellulose. The
membranes were blocked for 1h at room temperature in
3% milk and TBST (Tris pH 7.9, NaCl, Tween 20). Nitro-
cellulose blots were then probed with: primary monoclo-
nal antibody to APP (Millipore, Billerica, MA, USA)
1:1000 overnight at 48C; primary monoclonal antibody
to eIF-4E (BD Biosciences, Boston, MA, USA) 1:1000
overnight at 48C; primary polyclonal antibody to
CX37/GJA4 (LifeSpan Biosciences, Seattle, WA, USA)
1:500 overnight at 48C; primary polyclonal antibody to
GAPDH (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) 1:500 for 1h at room temperature; primary poly-
clonal antibody to phospho-p70s6Kinase (Cell Signaling
Technology, Danvers, MA, USA) 1:1000 overnight at
48C; primary polyclonal antibody to total p70s6Kinase
(Cell Signaling Technology) 1:1000 overnight at 48C; or
JunB (P169) (Cell Signaling Technology) 1:500 for 4h at
room temperature, all diluted in TBST. The blots were
then rinsed brieﬂy with TBST and incubated with anti-
mouse (1:10000) or anti-rabbit (1:50000) horseradish
Nucleic Acids Research, 2008, Vol. 36, No. 21 6837peroxidase-conjugated secondary antibody (Promega) for
1h at room temperature. Immunoreactive bands were
detected by developing the blots with ECL plus chemilu-
minescence reagents (GE Healthcare, Piscataway, NJ,
USA) and scanned with a Storm phosphorimager. Protein
expression levels were quantiﬁed using ImageQuant soft-
ware (GE Healthcare) and each lane normalized for
protein loading using GAPDH levels.
RNA Isolation
For RT–PCR experiment, TRI-Reagent (Sigma Aldrich)
was used to isolate total RNA from cells in culture.
Brieﬂy, RNA was isolated from the aqueous phase of
the TRI-reagent preparation, puriﬁed with phenol/
chloroform extraction and precipitated with isopropanol
followed by an ethanol wash. Dried and pelleted RNA
was resuspended in RNAse-free water (Ambion) and incu-
bated at 658C for 10–15min. For isolation of exogenous
RNA from RRL experiments, MegaClear (Ambion) was
used. For northern analysis of endogenous mRNA follow-
ing cellular treatments in C6 cells, total RNA was isolated
using RNAqueous (Ambion) as per manufacturer’s
speciﬁcations.
Northern blot analysis
Total RNA was isolated from samples as detailed above
and heat-denatured for 15min at 658C. For northerns of
endogenous RNA, 1mg was run on a 1.25% agarose gel
and transferred to a positive nylon membrane. RNA was
UV cross-linked to the membrane. Hybridization of the
DIG-labeled in vitro transcribed Photinus luciferase gene,
APP gene or GAPDH gene-speciﬁc probe was done over-
night at 688C. Anti-DIG-AP (Roche) identiﬁed the bound
probes and the addition of CDP-star substrate was used to
visualize RNA using X-ray ﬁlm exposure.
Reverse transcription and PCR
ImPROMII Reverse Transcription System (Promega) was
performed on total RNA. Nonspeciﬁc RNA primers
[Oligo(dT)] provided in the kit were used in the reverse
transcription reaction to amplify all mRNA. The positive
control was prepared as suggested in the product manual.
The ﬁrst negative control contained no RNA template but
did contain reverse transcriptase (RT) enzyme. The second
negative control did not contain RT enzyme but did con-
tain the RNA template. The RT reaction was carried out
as described in the product manual. PCR was performed
using Proofstart (Qiagen). For PCR, RT reaction prod-
ucts were ampliﬁed with 50-end primers to amplify
upstream of the Renilla codon (GGC CTA GGC TTT
TGC AAA) and 30-primers to amplify the Photinus
codon (ATC TTC CAG CGG ATA GAA TGG CGC
CGG). PCR cycles and temperature settings were applied
as per manufacturer’s instructions, except that the number
of ampliﬁcation cycles was increased to 50.
RESULTS
APP isendogenously synthesizedin an mTOR-independent
manner in neural cells
To determine if APP can be synthesized by a cap-
independent mechanism, rat neural C6 cells in culture
were treated for 16h with rapamycin to inhibit mamma-
lian target of rapamycin (mTOR) and consequently cap-
dependent translation (46). In the rapamycin-treated
cells, phosphorylation of p70s6 kinase (p70s6K), a protein
which is a substrate of mTOR, was dramatically dimin-
ished indicating that the drug treatment was eﬀective.
In the presence of rapamycin, the amount of full length
APP (mature  135kDa and immature  120kDa) (47)
actually increased by  50% demonstrating that APP con-
tinues to be synthesized when cap-dependent translation
is inhibited (Figure 1). We also observed similar results
in human neuroblastoma SH-SY5Y cells (Figure S1).
Figure 1. APP is endogenously synthesized in a cap-independent
manner in rat C6 glioma cells. C6 cells in culture were treated for
16h with either DMSO or rapamycin. Cell lysates were analyzed via
western blotting for (A) APP, phosphorylated p70s6 kinase and total
p70s6 kinase, (B) connexin37 and GAPDH as a loading control.
Imagequant Software was used to quantify APP expression from six
separate experiments.
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APP have found a half-life between 20min and 90min
(10–12). In C6 cells, we found a half-life of 45min for
the mature form of APP (135kDa) and a half-life of
19min for the immature form (120kDa) (Figure S2).
The rapid turnover of APP indicates that protein stability
did not confound interpretation of the results. Alterna-
tively, expression of connexin 37 protein was reduced
(Figure 1). This result is in agreement with the previous
observation of a loss of connexin 37 mRNA on polyribo-
somes following poliovirus infection (48). Taken together,
these results indicate that connexin 37 is translated in a
cap-dependent manner, while translation of APP can be
maintained or even increased when cap-dependent trans-
lation is diminished by inhibiting mTOR.
Knockdown of thecap-binding proteineIF-4E does
not affectendogenous APPexpression
To conﬁrm that APP mRNA can be translated in a cap-
independent manner, we knocked down expression of the
cap-binding protein eIF-4E (Figure 2). Rat C6 neural cells
were treated with siRNA directed against eIF-4E or with
control nonsense siRNA (Dharmacon). After 72h, APP
expression was equivalent in the eIF-4E siRNA and con-
trol siRNA cells despite the observation that eIF-4E pro-
tein was knocked down by >80%. JunB, whose mRNA
is translated by a cap-dependent mechanism (49), was
reduced in expression in cells treated with eIF-4E siRNA.
GAPDH was used as a loading control because it has a
very stable half-life, ranging from 90h to 120h (50).
The APP 5’-leader exhibits IRES activity
To determine whether the APP mRNA is translated via an
IRES in its 50-leader, we assayed the ability of the APP
50-leader and other 50-leaders to initiate translation when
placed in the intercistronic region of a dicistronic con-
struct (Figure 3) [dicistronic DNA constructs generously
provided by Dr Anne Willis (44)]. The constructs con-
tained the ORFs for Renilla luciferase and Photinus
luciferase and were transfected into C6 neural cells for
24h. Cell lysates were then obtained and assayed for lucif-
erase activity. Ratios of Photinus luciferase to Renilla
luciferase (P:R) obtained from each 50-leader construct
were normalized to the P:R ratio obtained from the con-
trol b-globin 50-leader construct. The b-globin mRNA is
translated exclusively in a cap-dependent manner (51).
P:R ratios above a value of 1 therefore indicate the pres-
ence of an IRES. The dicistronic construct containing the
encephalomyocarditis virus (EMCV) IRES was used as a
positive control and exhibited a P:R ratio of  8-fold over
the negative control (Figure 3A and B). The P:R ratio
from the dicistronic DNA containing the APP 50-leader
was  6-fold higher than the b-globin construct. A similar
ﬁnding was shown by Qin and Sarnow (17) using a com-
parable dicistronic luciferase DNA construct and suggests
that the APP 50-leader has an IRES.
The use of dicistronic DNA constructs has two major
limitations. Cryptic promoter or cryptic splice acceptor
activity may be present in the 50-leader leading to an
abundance of capped monocistronic Photinus luciferase
transcripts and thereby presenting an artiﬁcially augmen-
ted P:R ratio. To test for the presence of a cryptic promo-
ter in the APP 50-leader, the leader was inserted into the
intercistronic region of a promoterless dicistronic DNA
construct [graciously provided by Dr Anne Willis (52)].
We used the b-globin 50-leader as a negative control
and the full-length mouse neurotrophin receptor TrkB
50-leader as a positive control, which we showed previ-
ously to contain a cryptic promoter (53). When C6 cells
were transfected with the promoterless DNA constructs
for 24h, the APP 50-leader and EMCV IRES constructs
produced P:R ratios similar to that of the negative control
b-globin; while, the TrkB 50-leader exhibited a P:R ratio of
>200. This result indicates that the APP 50-leader does not
contain a cryptic promoter.
Figure 2. Knockdown of the cap-binding protein eIF-4E in rat C6 cells
does not aﬀect APP expression. (A) C6 cells were treated with either
nonsense siRNA or siRNA directed against eIF-4E and harvested after
72h. Western blotting was used to detect levels of APP, eIF-4E, JunB
and GAPDH. (B) Imagequant software was used to quantify protein
levels from ﬁve separate experiments.
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intron and a cryptic splice acceptor site in a 50-leader situ-
ated in the intercistronic region would result in the splicing
of the Renilla luciferase ORF. To determine whether the
APP 50-leader exhibits cryptic splicing activity, we trans-
fected C6 cells with the promoter-containing dicistronic
DNA constructs for 24h and ampliﬁed the resulting
RNA species using reverse transcriptase (RT) RT–PCR.
The 50-PCR primer was designed to lie upstream of the
Renilla ORF, while the 30-primer was designed to anneal
in the middle of the Photinus ORF as previously demon-
strated (54). With these primer designs, both mono- and
dicistronic RNA species would be ampliﬁed regardless of
the presence of the Renilla luciferase ORF in the RNA
transcript, as shown previously (54). Only single mRNA
species were observed from the transfections of the dicis-
tronic DNA constructs containing the b-globin or APP
50-leader at  1.5 KB, which is the size expected for
full-length dicistronic mRNA. Negative controls including
an RT reaction in absence of a template followed by PCR,
RT–PCR on total RNA from mock-transfected cells, no
RT enzyme and no PCR reaction (Figure 3D) did not
show any bands. This data indicate that the APP
50-leader does not contain a cryptic splice acceptor site.
Moreover, the data support the conclusion that the
enhanced P:R ratio from the APP 50-leader in the DNA
dicistronic constructs is due to the presence of an IRES.
Transfection ofdicistronic RNA confirms that
the APPmRNA 5’-leadercontainsan IRES
To overcome any possible limitations of the dicistronic
DNA constructs and validate the presence of an IRES
in the APP 50-leader, we in vitro transcribed dicistronic
m7GpppG (m7G)-capped and polyA-tailed mRNA
with intercistronically inserted 50-leader sequences and
Figure 3. The APP 50-leader exhibits IRES activity which cannot be attributed to the presence of a cryptic promoter or cryptic splice acceptor
activity. (A) C6 cells were transfected for 24h with dicistronic luciferase DNA constructs containing an SV40 promoter and the b-globin, APP,
EMCV or full-length mouse TrkB 50-leader inserted into the intercistronic region. (B) Luciferase activity is shown as the ratio of Photinus luciferase
to Renilla luciferase (P:R) and is normalized to the activity obtained from the construct containing the b-globin 50-leader. (C) C6 cells were
transfected for 24h with promoterless dicistronic luciferase DNA constructs containing the b-globin, APP, EMCV or mouse TrkB 50-leaders and
assayed for Photinus and Renilla luciferase activity. (D) C6 cells were transfected with promoter-containing dicistronic DNA constructs for 24h.
Total RNA was harvested and nonspeciﬁc RT was performed. cDNA products were then ampliﬁed with 50-primers annealing upstream of the Renilla
and 30-primers annealing to the Photinus cistron. PCR products were analyzed on a 1% agarose gel. Lane 1, Hi-Lo ladder (Bionexus, Oakland, CA,
USA); lane 2, no template; lane 3, mock transfection; lane 4, b-globin construct transfection; lane 5, APP construct transfection; lane 6, no RT
enzyme; and lane 7, no PCR reaction.
6840 Nucleic Acids Research, 2008, Vol. 36, No. 21transfected rat neural C6 cells with these individual
mRNAs. Seven hours later, the cell lysates were harvested
and assayed for luciferase activity. From these transfec-
tions, the dicistronic mRNA containing the APP 50-leader
RNA revealed a P:R ratio of nearly 5-fold over the nega-
tive control b-globin 50-leader (Figure 4), similar to the
P:R ratios obtained using dicistronic DNA construct
transfections (Figure 3B). This result further supports
the presence of an IRES in the APP 50-leader.
The APP 5’-leader can initiatetranslation independent
of the5’-m7Gcap structure invitro
While dicistronic constructs are useful tools to identify
IRESs, most eukaryotic mRNAs are monocistronic and
positioning of the IRES within the mRNA and in partic-
ular its distance from the 50-end of the mRNA may alter
its activity. Consequently, we examined the ability of the
APP 50-leader to initiate translation of a monocistronic
mRNA. In vitro transcribed monocistronic capped and
tailed mRNA containing the b-globin or APP 50-leaders
placed upstream of the Photinus luciferase ORF were
added to RRL. An increasing concentration of m7G cap
analog (New England Biolabs) was also added to com-
pete with the cap structure for eIF-4E and inhibit cap-
dependent translation. In the presence of 100mM of cap
analog, translation of the b-globin 50-leader-containing
RNA was reduced by >60% (Figure 5A). In contrast,
translation of the mRNA containing the APP 50-leader
was remarkably resistant to the eﬀects of cap analog addi-
tion. In fact, low concentrations of cap analog actually led
to an increase in Photinus luciferase activity, suggesting
there may be a competition between the cap and IRES
for the translation initiation machinery. At the highest
concentrations of cap analog, Photinus luciferase activity
from the APP 50-leader mRNA was equivalent to that
obtained from the untreated lysate. A 2-way ANOVA
conﬁrmed a signiﬁcant diﬀerence in protein expression
from the mRNAs containing the APP and b-globin
50-leaders (P<0.05). Moreover, northern blot analysis
did not show any diﬀerential change in the levels of the
two mRNAs after addition of cap analog indicating that
RNA stability was not confounding interpretation of the
results (Figure 5B). Consequently, this in vitro experiment
demonstrates that the APP 50-leader can mediate cap-
independent translation.
Figure 5. The APP 50-leader can initiate cap-independent translation
in vitro.( A) Monocistronic luciferase RNAs containing the 50-leader
from the b-globin and APP mRNAs inserted upstream of the Photinus
luciferase ORF were individually translated in micrococcal nuclease-
treated RRL in the presence of increasing concentrations of cap
analog. The initial level of Photinus luciferase activity from each
RNA was normalized to 100. (B) Northern blot analysis was performed
on monocistronic RNA isolated from the RRL in vitro translation
assays in presence of increasing amounts of cap analog to demonstrate
transcript integrity. RNA was probed with DIG-labeled in vitro tran-
scribed probe against Photinus luciferase.
Figure 4. Ex vivo transfection of dicistronic RNA conﬁrms that the
APP mRNA 50-leader contains an IRES. (A) Dicistronic luciferase
RNAs containing the 50-leader from the b-globin or APP mRNA
inserted into the intercistronic region of a dicistronic luciferase con-
struct were individually transfected into C6 cells. (B) Luciferase activity
is shown as the ratio of Photinus luciferase to Renilla luciferase (P:R)
and is normalized to the activity obtained from the mRNA containing
the b-globin 50-leader.
Nucleic Acids Research, 2008, Vol. 36, No. 21 6841The 5’50nt ofthe APP 5’-leader aresufficient to
internally initiate translation
To locate the region within the APP 50-leader that is
required for basal IRES activity, the 50-leader was divided
into three nonoverlapping regions of 44–53nt (APPa,
APPb and APPc; Figure 6). When C6 cells were trans-
fected with dicistronic RNAs containing APPa, APPb or
APPc 50-leader regions, only APPa exhibited IRES activ-
ity above control levels (Figure 6), although total IRES
activity from the APPa leader was reduced by approxi-
mately half of the full-length APP leader. This result indi-
cates that the minimal sequence to initiate translation is
<50nt. However, the full-length 50-leader is required for
optimum IRES activity.
The APP5’-leaderinitiates translation cap-independently
ex-vivo
To assess the eﬀect of the APP 50 leader on translation, the
b-globin and APP 50-leaders were individually placed
upstream of the Photinus luciferase ORF. The b-globin
50-leader is short and unstructured and should be an excel-
lent substrate for cap-dependent translation; while the
APP 50-leader is longer, G/C rich and presumably more
structured than the b-globin 50-leader. Monocistronic
RNA was in vitro transcribed and capped with an m7G
cap or an ApppG cap. Inclusion of the ApppG cap inhi-
bits 50-t o3 0-exonuclease activity, but it does not bind to
eIF-4E and therefore cannot initiate cap-dependent trans-
lation. The mRNA was co-transfected with an m7G-
capped mRNA coding for humanized Renilla luciferase
(phRL, Promega) to normalize for transfection eﬃciency.
Following a 7h transfection into C6 cells, Photinus and
Renilla luciferase activity was assayed. The m7G-capped
RNA containing the b-globin 50-leader was translated very
eﬃciently at a level of  2.5-fold over the m7G-capped
RNA containing the APP 50-leader (Figure 7). However,
these translational diﬀerences were reversed when ApppG
capped RNA was examined. In this situation, translation
of the RNA containing the APP 50-leader was >3-fold
higher than the ApppG capped b-globin reporter RNA
(Figure 7). These results indicate that basal APP transla-
tion may be lower than mRNAs with less structured and
G/C rich 50-leaders, but more importantly it demonstrates
that the APP 50-leader can initiate cap-independent trans-
lation in cells. Additionally, it supports the hypothesis
that during events when eIF-4E is not utilized (when
the N-terminus of eIF-4G is cleaved or during an upregu-
lation of the homolog of the eIF-4G c-terminus—
DAP5/p97), synthesis of APP can be maintained in a
cap-independent manner.
Increased intracellular iron concentration and chemical
ischemia increase cap-independent translation of APP
In postmortem AD brain, an increase in intracellular
iron concentration is often evident and coincident with
Figure 7. The APP 50-leader demonstrates IRES activity in a mono-
cistronic context. Monocistronic Photinus reporter mRNA with the
b-globin or APP 50-leader downstream of either an m7G cap or
ApppG cap were co-transfected with monocistronic m7G-capped
humanized Renilla luciferase mRNA, to normalize for transfection
eﬃciency, into C6 cells. Following a 7h transfection into C6 cells,
Photinus and Renilla luciferase activities were assayed.
Figure 6. The 50 50nt of the APP 50-leader are suﬃcient to internally
initiate translation. The APP 50-leader was divided into three nonover-
lapping regions (see schematic) consisting of the 50 50nt (APPa), the
internal 44nt containing the IRE (APPb) and the 30 53nt (APPc). The
three APP segments along with the full-length APP 50-leader and
b-globin 50-leader were inserted into the intercistronic region of the
dicistronic luciferase mRNA and transfected into C6 cells. The P:R
ratio is normalized to the activity obtained from the mRNA containing
the b-globin 50-leader.
6842 Nucleic Acids Research, 2008, Vol. 36, No. 21presence of Ab plaques (28,29). In addition, there is often
evidence in postmortem brain of acute ischemic injury.
Iron aﬀects protein synthesis at multiple levels (33);
while ischemia and reperfusion inhibits cap-dependent
translation (41). Therefore, we examined whether ex vivo
treatments which mimic these conditions correlated with
AD, namely excess intracellular iron and ischemia, could
augment endogenous levels of APP.
To determine if translation of the endogenous APP
mRNA is aﬀected by iron or ischemic conditions, C6
cells were treated either with FAC for 24h or acutely
with chemical ischemia reagents for 10min. Both treat-
ments were performed in the absence or presence of rapa-
mycin to inhibit mTOR and diminish cap-dependent
translation (Figure 8). FAC is a soluble ferric iron com-
plex which is a good source for increasing intracellular
iron in neural cells (55). To mimic ischemia and reperfu-
sion, C6 cells were treated for 10min with 10mM sodium
azide (an inhibitor of oxidative phosphorylation) and
10mM dideoxyglucose (an inhibitor of glycolysis) (56),
and then placed back into complete growth media for
7h. Regardless of the presence or absence of rapamycin,
both FAC and chemical ischemia increased APP expres-
sion, ranging from 50% to 80%. Moreover, rapamycin by
itself also increased APP expression by 50% (Figure 8;
also see Figure 1). This result suggests that iron and chem-
ical ischemia stimulate cap-independent translation of
endogenous APP. Similar results were observed in the
undiﬀerentiated human dopaminergic neuroblastoma
cell line, SH-SY5Y (Figure S1B). Interestingly, FAC and
chemical ischemia did not decrease phosphorylation of
p70s6kinase, suggesting that stimulating cap-independent
translation of APP by these reagents does not require
inhibition of the mTOR pathway.
To determine whether protein or RNA stability inﬂu-
enced these results, we performed a western and northern
blot analysis, respectively. For protein expression, C6 cells
exposed to the diﬀerent treatments were treated with
cycloheximide for the last 30 or 60min of the experi-
ment. The results show that APP protein stability was
unaﬀected (Figure S3A and S3B). A northern blot analysis
of RNA obtained from C6 cells exposed to the diﬀerent
stimuli showed that RNA stability was also unaﬀected
(Figure S3C). Taken together, these results indicate that
cap-independent translation is utilized for the translation
of the endogenous APP mRNA both in a basal state and
in response to the stressful cellular conditions induced by
excess iron and ischemia.
APPIRES activity isaugmented byiron treatment
To determine whether iron treatment augments APP
IRES activity, we exposed C6 cells to FAC for 24h.
During the ﬁnal 7h of FAC treatment, the cells were
transfected with dicistronic RNA containing the
b-globin or APP 50-leaders (Figure 9). Iron had no signiﬁ-
cant eﬀect on the P:R ratio obtained from the b-globin
50-leader. However, the P:R ratio obtained from the RNA
containing the APP 50-leader was enhanced by 1.7-fold,
from 4.0 to 6.8. This result indicates that activity of the
APP IRES is positively regulated by iron.
The APP 50-leader has previously been reported to con-
tain an iron-responsive element [IRE; (32)]. IREs modu-
late the stability and translation of a number of mRNAs
coding for proteins involved in iron metabolism through
their binding to iron regulatory proteins [IRPs; (57)].
To determine if the APP 50-leader IRE is required for
the iron-induced increase in IRES activity, 4nt of the
IRE were deleted (APP, see schematic in Figure 6).
This deletion inhibits binding of IRPs to the APP IRE,
as well as the IREs in the ferritin light- and heavy-
chain mRNAs (32,58). Transfection of dicistronic RNA
containing the APP 50-leader showed that the ability
of iron to enhance APP IRES activity still persisted
(Figure 9). The mutation resulted in a decrease of the
basal level of APP IRES activity by approximately half,
but the enhancement of the basal IRES activity remained
Figure 8. ex vivo conditions which mimic the AD brain state lead to an increase in cap-independent translation of APP. Rat neural C6 cells were
either treated with FAC for 24h or acutely with chemical ischemia reagents (sodium azide and dideoxyglucose), for 10min, 7h prior to harvest both
treatments carried out in the absence or presence of rapamycin for 16h. Cell lysates were probed for (A & B) APP, phospho-p70s6 kinase and
GAPDH levels using Western blotting. (C) APP levels were quantiﬁed using Molecular Dynamics Imagequant software and normalized for protein
loading. APP protein levels were normalized to DMSO (untreated) controls. Data graphed represent ﬁve separate experiments.
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This result indicates that the putative IRE in the APP
50-leader aﬀects internal initiation mediated by the APPa
region (Figure 6), but it is not required for the iron-
induced increase in APP IRES activity.
The mechanism and regulation of IRES-dependent
translation of eukaryotic mRNAs is not well understood.
However, the utilization of internal initiation of transla-
tion often coincides with periods when global changes in
transcription occur, including during mitosis and apopto-
sis (24). This observation suggests that protein products
of genes which are preferentially transcribed during these
periods may regulate IRES-dependent translation. To
determine whether de novo transcription is required for
the iron-induced increase in IRES activity, C6 cells were
either untreated or treated with FAC in the presence or
absence of actinomycin D (an inhibitor of de novo tran-
scription) and then transfected with dicistronic RNAs
containing the b-globin, APP and APPa 50-leaders
(Figure 10). Exposure to iron not only increased the P:R
ratio obtained from the APP dicistronic RNA, but the P:R
ratio from the APPa RNA was also enhanced by almost
2-fold with iron. Interestingly, the iron-induced increase
in IRES activity mediated by both the APP and APPa
50-leaders was abolished in the presence of actinomycin
D. Cells treated only with actinomycin D did not exhibit
any change from the basal P:R ratio. These results indic-
ate that the 50 50nt of the APP 50-leader (APPa) is suﬃ-
cient to exhibit the iron-enhanced increase in IRES
activity and furthermore this augmentation requires de
novo transcription.
APP IRESactivity is stimulated by chemical ischemia
To determine if APP IRES activity is speciﬁcally enhanced
by ischemia, we transfected dicistronic RNAs into C6 cells
and acutely (10min) treated the cells with the chemical
ischemia reagents sodium azide and dideoxyglucose as
previously described (56). After 7h, we assayed for lucif-
erase activity. The P:R ratio obtained from the b-globin
50-leader RNA was unaltered in response to chemically
induced ischemia (Figure 11). However, the P:R ratio
from both the APP and APPa 50-leaders were increased
by 1.4- and 1.5-fold, respectively. This ischemia-induced
enhancement of IRES activity was abolished in the pres-
ence of actinomycin D, a result similar to that observed
with the iron-enhanced increase in APP IRES activity
(Figure 10). These results indicate that de novo transcrip-
tion is required for the enhancement of APP IRES activity
by chemical ischemia and that the 50 50nt of the APP
50-leader are suﬃcient to mediate this augmentation of
IRES activity.
DISCUSSION
In the present report, we show that endogenous APP can
be translated in a cap-independent manner in neural cells
in the presence of rapamycin or in the absence of the cap-
binding protein eIF-4E. Additionally, endogenous APP
translation is enhanced by iron and chemical ischemia
treatment even when cap-dependent translation is inhib-
ited using rapamycin. These observations led us to conﬁrm
Figure 10. The 50 50nt of the APP 50-leader are suﬃcient to mediate the
iron-enhanced increase in APP IRES activity, a process which requires
de novo transcription. Dicistronic luciferase mRNA containing the b-
globin, APP or APPa 50-leader were transfected into C6 cells and trea-
ted with complete growth medium, FAC, FAC and actinomycin D or
actinomycin D alone. The P:R ratio is normalized to the activity
obtained from the mRNA containing the b-globin 50-leader under
each individual treatment.
Figure 9. Iron exposure increases APP 50-leader IRES activity inde-
pendently of the IRE. Dicistronic luciferase mRNA containing the
b-globin, APP 50-leader, or APP 50-leader with the IRE mutated
(APP) in the intercistronic region were transfected individually into
C6 cells which had been treated for a total of 24h with FAC-supple-
mented media or with complete culture media. Luciferase activity is
shown as the ratio of Photinus luciferase to Renilla luciferase (P:R)
and is normalized to the activity obtained from the mRNA containing
the b-globin 50-leader.
6844 Nucleic Acids Research, 2008, Vol. 36, No. 21that the APP 50-leader contains an IRES using a combina-
tion of RNA and DNA reporter constructs. Moreover,
the IRES was localized to the 50 50nt of the 50-leader.
APP IRES activity was also enhanced by increased intra-
cellular iron concentration and chemical ischemia, both
eﬀects which were dependent upon de novo transcription.
Taken together, these results indicate that IRES-
dependent translation of the APP mRNA may be physio-
logically relevant.
Mechanism of invivo translation of APPmRNA
In the present studies, we provide support for the bio-
logical relevance of the APP IRES. APP synthesis was
maintained and even enhanced when cap-dependent
translation was reduced. Moreover, even under these
translation-repressing conditions, iron and chemical ische-
mia treatments led to an increase in APP expression
without aﬀecting protein or RNA stability.
It is possible that rapamycin treatment and knockdown
of eIF-4E may also be perceived as a stressful event by the
cell and consequently upregulate IRES-dependent trans-
lation. However, methods to selectively reduce IRES-
dependent translation without aﬀecting cap-dependent
translation are relatively unknown. To date, only hypo-
morphic alleles of the gene dyskerin have been shown
to repress IRES activity (25). Nonetheless, in vitro and
ex vivo assays demonstrated that the APP 50-leader is
capable of initiating translation at levels similar to cap-
dependent translation. These results support the premise
that IRES-dependent translation can be as eﬃcient as
cap-dependent translation.
Regulating APPIRES activity
Two perturbations, an increase in intracellular iron and a
decrease in oxygen are proposed to exacerbate AD
(28,35). In the current studies, both conditions led to
increased endogenous APP expression and APP IRES
activity. Interestingly, the increase in APP IRES activity
required de novo transcription. IRES trans-acting factors
(ITAFs) are proposed to be one of the rate-limiting factors
for eukaryotic IRESs as well as for some viral IRESes [for
review, see Ref. (59)]. ITAFs are thought to be molecular
chaperones which bind the 50-leader and either maintain
the secondary structure or alter it in such a way that the
ribosomal subunits and/or canonical eukaryotic transla-
tion initiation factors can bind and facilitate initiation of
translation (20). Consequently, it is tempting to speculate
that increased intracellular iron and chemical ischemia
treatments enhance transcription of a particular ITAF.
However, multiple scenarios could be occurring, including
synthesis of ITAFs which compete with already-present
inhibitory ITAFs (60,61) for binding sites in the APP
mRNA 50-leader, thus alleviating repression of IRES
activity.
Dissecting theAPP IRES
The minimal functional unit of the APP IRES is located
in the 50 50nt of the APP 50 leader and this 50 region is
suﬃcient for both iron- and ischemia-enhanced IRES
activity. Post-transcriptional regulation of mammalian
genes involved in iron metabolism is often mediated by
an IRE (57). Rogers and colleagues (32) have proposed
that APP synthesis is regulated through a unique type II
IRE in the APP 50-leader and found that chelating iron
inhibits IRP binding to the APP IRE as well as APP
synthesis. The type II APP IRE is unusual; traditionally,
binding of an IRP to an IRE occurs in the presence of iron
[as previously observed for IRP binding to the ferritin and
transferrin receptor IREs (62)], while IRPs proposed to
bind the type II APP IRE occur in the absence of iron
(32). Interestingly, abrogating IRP binding by deleting
four nucleotides within the IRE (32) also led to a decrease
in basal APP IRES activity. This result suggests that IRP
binding to the APP IRE may act as an ITAF and enhance
IRES activity, since deletion of this entire region is dis-
pensable for IRES activity (Figure 6).
The intracellular pathway which links iron and ischemia
to an enhancement in APP IRES activity is unknown.
However, oxidative stress is a common downstream
aﬀect of excess intracellular iron [for review see Ref. (63)
and ischemia (64)]. Iron contributes to the production of
hydroxyl radicals through the Fenton reaction (65).
Ischemia results in the production of peroxynitrite also
leading to hydroxyl radical formation (66). Intracellular
signaling pathways elicited by free radicals can alter tran-
scription and may link iron and ischemia to enhanced
APP IRES activity. Alternatively, distinct mechanisms
could mediate the iron and ischemia response. For exam-
ple, increased levels of labile iron enhances synthesis of
ferritin, which along with a ferritin-like protein K562,
can bind DNA and alter transcription (67,68).
Regulating APP synthesis as atherapeutictarget in AD
Inhibiting APP expression is a viable target for the treat-
ment of AD. Expression of APP can be regulated at
transcriptional, translational or protein levels. Our present
results indicate that the APP mRNA is translated in an
IRES-dependent mechanism. This work further elucidates
Figure 11. Chemical ischemia enhances APP IRES activity in a
transcription-dependent manner. Dicistronic luciferase RNAs contain-
ing the b-globin, APP or APPa 50-leaders were transfected into C6 cells
and treated with either complete medium or complete medium with a
10min exposure to sodium azide and dideoxyglucose in the absence or
presence of actinomycin D. The P:R ratio is normalized to the activity
obtained from the mRNA containing the b-globin 50-leader.
Nucleic Acids Research, 2008, Vol. 36, No. 21 6845the mechanism for the translation of APP and provides
a new avenue for exploration. If ITAFs are indeed a
rate-limiting step for eukaryotic IRES translation, then
studies directed toward identifying ITAFs that bind the
APP 50-leader and designing mimetics to interfere with
the binding may be a useful approach toward the treat-
ment of AD.
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